29941-82-0Relevant articles and documents
Oxidative Alkoxylation/Dehydrogenation of Unactivated Cyclic Ketones with Simple Alcohols: Direct Route to α-Alkoxy Cycloenones
Yan, Yizhe,Li, Shaoqing,Wang, Jianyong
, p. 6474 - 6477 (2020)
An oxidative functionalization of cyclopentanones or cyclohexanones with simple alcohols was first demonstrated, affording a series of 2-alkoxycyclopent-2-en-1-ones or 2-alkoxycyclohex-2-en-1-ones in moderate to excellent yields. The reaction was involved in tandem iodization, substitution, oxidation and addition-elimination processes in one pot. This method is highly atom-economical and operationally simple.
HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS
-
Page/Page column 154, (2018/10/19)
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl] amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor
Brasca, Maria Gabriella,Amboldi, Nadia,Ballinari, Dario,Cameron, Alexander,Casale, Elena,Cervi, Giovanni,Colombo, Maristella,Colotta, Francesco,Croci, Valter,D'Alessio, Roberto,Fiorentini, Francesco,Isacchi, Antonella,Mercurio, Ciro,Moretti, Walter,Panzeri, Achille,Pastori, Wilma,Pevarello, Paolo,Quartieri, Francesca,Roletto, Fulvia,Traquandi, Gabriella,Vianello, Paola,Vulpetti, Anna,Ciomei, Marina
experimental part, p. 5152 - 5163 (2010/03/04)
The discovery of a novel class of inhibitors of cyclin dependent kinases (CDKs) is described. Starting from compound 1, showing good potency as inhibitor of CDKs but being poorly selective against a panel of serine-threonine and tyrosine kinases, new analogues were synthesized. Enhancement in selectivity, antiproliferative activity against A2780 human ovarian carcinoma cells, and optimization of the physical properties and pharmacokinetic profile led to the identification of highly potent and orally available compounds. Compound 28 (PHA-848125), which in the preclinical xenograft A2780 human ovarian carcinoma model showed good efficacy and was well tolerated upon repeated daily treatments, was identified as a drug candidate for further development. Compound 28 is currently undergoing phase I and phase II clinical trials.